LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

Search

Penumbra Inc

Open

SectorHealthcare

278.9 -0.18

Overview

Share price change

24h

Current

Min

274.31

Max

283.24

Key metrics

By Trading Economics

Income

6M

45M

Sales

15M

339M

P/E

Sector Avg

59.839

77.256

Profit margin

13.336

Employees

4,500

EBITDA

1.9M

51M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+13.41% upside

Market Stats

By TradingEconomics

Market Cap

-92M

8.8B

Previous open

279.08

Previous close

278.9

News Sentiment

By Acuity

50%

50%

180 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Penumbra Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 lis 2025, 23:59 UTC

Earnings

Singtel's 1st Half Net Profit Surges

11 lis 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11 lis 2025, 22:21 UTC

Earnings

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11 lis 2025, 23:52 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11 lis 2025, 23:44 UTC

Earnings

Singtel's 1H Net Profit Surges

11 lis 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11 lis 2025, 23:18 UTC

Earnings

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11 lis 2025, 23:15 UTC

Earnings

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11 lis 2025, 23:14 UTC

Earnings

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11 lis 2025, 23:12 UTC

Earnings

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11 lis 2025, 23:11 UTC

Earnings

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11 lis 2025, 23:10 UTC

Earnings

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11 lis 2025, 23:04 UTC

Market Talk

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11 lis 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 lis 2025, 21:50 UTC

Market Talk
Earnings

Health Care Roundup: Market Talk

11 lis 2025, 21:46 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11 lis 2025, 21:41 UTC

Earnings

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11 lis 2025, 21:40 UTC

Earnings

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11 lis 2025, 21:39 UTC

Earnings

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11 lis 2025, 21:39 UTC

Earnings

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11 lis 2025, 21:39 UTC

Earnings

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11 lis 2025, 21:38 UTC

Earnings

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11 lis 2025, 21:38 UTC

Earnings

Aristocrat: Final Dividend 49 Australian Cents/Share

11 lis 2025, 21:37 UTC

Earnings

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11 lis 2025, 21:36 UTC

Earnings

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11 lis 2025, 21:35 UTC

Earnings

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11 lis 2025, 21:35 UTC

Earnings

Alcon 3Q Adj EPS 79c >ALC

11 lis 2025, 21:35 UTC

Earnings

Alcon 3Q Rev $2.61B >ALC.EB

11 lis 2025, 21:35 UTC

Earnings

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11 lis 2025, 21:35 UTC

Earnings

Alcon 3Q EPS 48c >ALC.EB

Peer Comparison

Price change

Penumbra Inc Forecast

Price Target

By TipRanks

13.41% upside

12 Months Forecast

Average 306.82 USD  13.41%

High 355 USD

Low 266 USD

Based on 13 Wall Street analysts offering 12 month price targets forPenumbra Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

10

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

288.28 / 292.9394Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

180 / 374 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat